Literature DB >> 20605983

Role of tumor necrosis factor alpha in disease using a mouse model of Shiga toxin-mediated renal damage.

Erin K Lentz1, Rama P Cherla, Valery Jaspers, Bradley R Weeks, Vernon L Tesh.   

Abstract

Mice have been extensively employed as an animal model of renal damage caused by Shiga toxins. In this study, we examined the role of the proinflammatory cytokine tumor necrosis factor alpha (TNF-alpha) in the development of toxin-mediated renal disease in mice. Mice pretreated with TNF-alpha and challenged with Shiga toxin type 1 (Stx1) showed increased survival compared to that of mice treated with Stx1 alone. Conversely, mice treated with Stx1 before TNF-alpha administration succumbed more quickly than mice given Stx1 alone. Increased lethality in mice treated with Stx1 followed by TNF-alpha was associated with evidence of glomerular damage and the loss of renal function. No differences in renal histopathology were noted between animals treated with Stx1 alone and the TNF-alpha pretreatment group, although we noted a sparing of renal function when TNF-alpha was administered before toxin. Compared to that of treatment with Stx1 alone, treatment with TNF-alpha after toxin altered the renal cytokine profile so that the expression of proinflammatory cytokines TNF-alpha and interleukin-1beta (IL-1beta) increased, and the expression of the anti-inflammatory cytokine IL-10 decreased. Increased lethality in mice treated with Stx1 followed by TNF-alpha was associated with higher numbers of dUTP-biotin nick end labeling-positive renal tubule cells, suggesting that increased lethality involved enhanced apoptosis. These data suggest that the early administration of TNF-alpha is a candidate interventional strategy blocking disease progression, while TNF-alpha production after intoxication exacerbates disease.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20605983      PMCID: PMC2937432          DOI: 10.1128/IAI.00616-10

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  55 in total

Review 1.  Pathways followed by ricin and Shiga toxin into cells.

Authors:  Kirsten Sandvig; Stine Grimmer; Silje Ugland Lauvrak; Maria Lyngaas Torgersen; Grethe Skretting; Bo van Deurs; Tore Geir Iversen
Journal:  Histochem Cell Biol       Date:  2001-11-20       Impact factor: 4.304

Review 2.  Shiga toxins.

Authors:  K Sandvig
Journal:  Toxicon       Date:  2001-11       Impact factor: 3.033

Review 3.  Pathogenesis of Shiga toxin-associated hemolytic uremic syndrome.

Authors:  F Proulx; E G Seidman; D Karpman
Journal:  Pediatr Res       Date:  2001-08       Impact factor: 3.756

4.  Molecular and functional analysis of Shiga toxin-induced response patterns in human vascular endothelial cells.

Authors:  Andreas Matussek; Joerg Lauber; Anna Bergau; Wiebke Hansen; Manfred Rohde; Kurt E J Dittmar; Matthias Gunzer; Michael Mengel; Patricia Gatzlaff; Maike Hartmann; Jan Buer; Florian Gunzer
Journal:  Blood       Date:  2003-04-17       Impact factor: 22.113

5.  Bcl-2 antiapoptotic protein mediates verotoxin II-induced cell death: possible association between bcl-2 and tissue failure by E. coli O157:H7.

Authors:  A Suzuki; H Doi; F Matsuzawa; S Aikawa; K Takiguchi; H Kawano; M Hayashida; S Ohno
Journal:  Genes Dev       Date:  2000-07-15       Impact factor: 11.361

6.  Serum amyloid P component is the Shiga toxin 2-neutralizing factor in human blood.

Authors:  T Kimura; S Tani; Y Matsumoto Yi; T Takeda
Journal:  J Biol Chem       Date:  2001-08-31       Impact factor: 5.157

7.  Shiga toxin 1 triggers a ribotoxic stress response leading to p38 and JNK activation and induction of apoptosis in intestinal epithelial cells.

Authors:  Wendy E Smith; Anne V Kane; Sausan T Campbell; David W K Acheson; Brent H Cochran; Cheleste M Thorpe
Journal:  Infect Immun       Date:  2003-03       Impact factor: 3.441

8.  Molecular basis for up-regulation by inflammatory cytokines of Shiga toxin 1 cytotoxicity and globotriaosylceramide expression.

Authors:  Peter K Stricklett; Alisa K Hughes; Zuhal Ergonul; Donald E Kohan
Journal:  J Infect Dis       Date:  2002-09-13       Impact factor: 5.226

9.  Differential tissue targeting and pathogenesis of verotoxins 1 and 2 in the mouse animal model.

Authors:  Niels W P Rutjes; Beth A Binnington; Charles R Smith; Mark D Maloney; Clifford A Lingwood
Journal:  Kidney Int       Date:  2002-09       Impact factor: 10.612

10.  Kinetic analysis of binding between Shiga toxin and receptor glycolipid Gb3Cer by surface plasmon resonance.

Authors:  H Nakajima; N Kiyokawa; Y U Katagiri; T Taguchi; T Suzuki; T Sekino; K Mimori; T Ebata; M Saito; H Nakao; T Takeda; J Fujimoto
Journal:  J Biol Chem       Date:  2001-09-13       Impact factor: 5.157

View more
  10 in total

Review 1.  Shiga toxins expressed by human pathogenic bacteria induce immune responses in host cells.

Authors:  Moo-Seung Lee; Myung Hee Kim; Vernon L Tesh
Journal:  J Microbiol       Date:  2013-12-19       Impact factor: 3.422

2.  Shiga toxin subtypes display dramatic differences in potency.

Authors:  Cynthia A Fuller; Christine A Pellino; Michael J Flagler; Jane E Strasser; Alison A Weiss
Journal:  Infect Immun       Date:  2011-01-03       Impact factor: 3.441

3.  NLRP3 inflammasome activation triggers gasdermin D-independent inflammation.

Authors:  Chun Wang; Tong Yang; Jianqiu Xiao; Canxin Xu; Yael Alippe; Kai Sun; Thirumala-Devi Kanneganti; Joseph B Monahan; Yousef Abu-Amer; Judy Lieberman; Gabriel Mbalaviele
Journal:  Sci Immunol       Date:  2021-10-22

4.  Distinct renal pathology and a chemotactic phenotype after enterohemorrhagic Escherichia coli shiga toxins in non-human primate models of hemolytic uremic syndrome.

Authors:  Deborah J Stearns-Kurosawa; Sun-Young Oh; Rama P Cherla; Moo-Seung Lee; Vernon L Tesh; James Papin; Joel Henderson; Shinichiro Kurosawa
Journal:  Am J Pathol       Date:  2013-02-10       Impact factor: 4.307

5.  Lipopolysaccharide renders transgenic mice expressing human serum amyloid P component sensitive to Shiga toxin 2.

Authors:  Thomas P Griener; Jonathan G Strecker; Romney M Humphries; George L Mulvey; Carmen Fuentealba; Robert E W Hancock; Glen D Armstrong
Journal:  PLoS One       Date:  2011-06-24       Impact factor: 3.240

Review 6.  Shiga Toxins as Multi-Functional Proteins: Induction of Host Cellular Stress Responses, Role in Pathogenesis and Therapeutic Applications.

Authors:  Moo-Seung Lee; Sunwoo Koo; Dae Gwin Jeong; Vernon L Tesh
Journal:  Toxins (Basel)       Date:  2016-03-17       Impact factor: 4.546

7.  Anti-high mobility group box-1 (HMGB1) antibody attenuates kidney damage following experimental crush injury and the possible role of the tumor necrosis factor-α and c-Jun N-terminal kinase pathway.

Authors:  Bin-Fei Zhang; Peng-Fei Wang; Yu-Xuan Cong; Jin-Lai Lei; Hu Wang; Hai Huang; Shuang Han; Yan Zhuang
Journal:  J Orthop Surg Res       Date:  2017-07-12       Impact factor: 2.359

8.  LPS-primed CD11b+ leukocytes serve as an effective carrier of Shiga toxin 2 to cause hemolytic uremic syndrome in mice.

Authors:  Shuo Niu; John Paluszynski; Zhen Bian; Lei Shi; Koby Kidder; Yuan Liu
Journal:  Sci Rep       Date:  2018-03-05       Impact factor: 4.379

Review 9.  Roles of Shiga Toxins in Immunopathology.

Authors:  Moo-Seung Lee; Vernon L Tesh
Journal:  Toxins (Basel)       Date:  2019-04-09       Impact factor: 4.546

Review 10.  Ribosomal stress-surveillance: three pathways is a magic number.

Authors:  Anna Constance Vind; Aitana Victoria Genzor; Simon Bekker-Jensen
Journal:  Nucleic Acids Res       Date:  2020-11-04       Impact factor: 16.971

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.